SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice

The CRISPR/Cas9 system has recently emerged as a highly efficient modality in genetic engineering and has been widely considered for various therapeutic applications. However, since the effector protein, SpCas9, has a bacterial origin, its immunogenicity must be explored in further depth. Here, we f...

Descripción completa

Detalles Bibliográficos
Autores principales: Ajina, Reham, Zamalin, Danielle, Zuo, Annie, Moussa, Maha, Catalfamo, Marta, Jablonski, Sandra A., Weiner, Louis M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492962/
https://www.ncbi.nlm.nih.gov/pubmed/31069138
http://dx.doi.org/10.1080/2162402X.2019.1577127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492962/
https://www.ncbi.nlm.nih.gov/pubmed/31069138
http://dx.doi.org/10.1080/2162402X.2019.1577127

Ejemplares similares